Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer.
Guan-Zhen. Yu Y; Ying. Chen C; Can-Rong. Ni N; Guo-Dong. Wang W; Jian-Xin. Qian Q; Jie-Jun. Wang W
Key Findings
- KISS1 protein levels drop in metastatic gastric cancer tissue
- Other metastasis‑suppressor proteins (nm23, KAI1) also decrease in metastases
- p53 protein shows the opposite pattern, increasing in metastases
Practical Outcomes
- For biohackers, this research mainly confirms that kisspeptin acts as a metastasis‑suppressor, but it doesn’t provide a clear way to use or boost kisspeptin for health or longevity. No dosing or supplementation guidance is offered, so the findings are more of scientific interest than a direct protocol.
Summary
The study found that the protein made by the KISS1 gene (kisspeptin) is lower in stomach cancer that has spread to lymph nodes and liver compared to the original tumor, hinting that less kisspeptin may help cancer spread.
Abstract
Metastasis remains an incurable common complication in patients with gastric cancer. A variety of theories have been proposed to explain the inefficiency of the metastatic process. To compare protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) between primary tumours and metastatic tumours may be useful in illustrating these theories. Metastasis-related tissue microarrays (including normal tissues, primary tumours, nodal metastases and liver metastases) were constructed. The protein expression of nm23, KISS1, KAI1 and p53 in lymph node and liver metastases from advanced gastric cancer specimens was mainly examined by immunohistochemical staining in relation to primary tumours. Immunohistochemical staining showed reduced protein expression of nm23, KISS1 and KAI1 in lymph node and liver metastases compared with primary tumours. Results for p53 were to the contrary. Our investigations revealed a tendency of reduced protein expression of metastasis suppressor genes nm23, KISS1 and KAI1 in gastric cancer with the progress of metastasis. This means that the progression theory is an important determinant of metastatic efficiency.
Study Information
pubmed
2007
2007-06-01T00:00:00.000Z
10.1111/j.1365-2613.2006.00510.x
75
41